Moneyweb2h
Novo Nordisk’s worst month since 2002
As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.
PGIM Jennison Focused Growth Fund Q4 2024 Commentary
The PGIM Jennison Focused Growth Fund rose 5.7%, slightly underperforming the Russell 1000 Growth Index. Click here to read the full commentary.
Novo Nordisk’s Worst Month Since 2002 Highlights Growth Concerns
As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued ...
In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly
The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.
Novo Nordisk: Finally A Buying Opportunity
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.